Tapering from Methadone or Buprenorphine during Pregnancy: Maternal and Neonatal Outcomes in Norway 1996-2009
| Autor: | Svetlana Skurtveit, Edle Ravndal, Lars Tanum, Brittelise Bakstad, Helge Waal, Lisa Bjarkø, Gabrielle K. Welle-Strand |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Narcotics medicine.medical_specialty Health (social science) Narcotic Antagonists Medicine (miscellaneous) Norwegian Drug Administration Schedule Pregnancy Opiate Substitution Treatment medicine Birth Weight Humans Prospective Studies Prospective cohort study Retrospective Studies Fetus Norway business.industry Obstetrics Infant Newborn Pregnancy Outcome Retrospective cohort study medicine.disease language.human_language Buprenorphine Psychiatry and Mental health Opioid Anesthesia language Female business Methadone medicine.drug |
| Zdroj: | European Addiction Research. 21:253-261 |
| ISSN: | 1421-9891 1022-6877 |
| DOI: | 10.1159/000381670 |
| Popis: | Background: The tapering of methadone or buprenorphine during pregnancy is an understudied and controversial issue. The aim of this study was to determine to what extent women tapered their opioid medication dose during pregnancy and what the neonatal outcomes were for those who tapered compared to the women who did not. Methods: The study was a mixed prospective/retrospective national cohort study of 123 Norwegian women in opioid maintenance treatment (OMT) during pregnancy and their neonates. A standardized questionnaire was administered to the women and medical information that could be used for verification was collected from hospitals and municipalities. Results: Two of the women came off the OMT-medication during pregnancy and another 15% tapered their OMT-medication dose more than 50%. The birth weights of methadone-exposed neonates of the women who tapered more than 50% were significantly higher than for the methadone-exposed neonates of the women tapering between 11 and 50%. No other significant differences were found. Conclusion: Pregnant women in OMT who taper their OMT-medication dose should be monitored closely. We need studies that document the maternal well-being and fetal safety of maternal tapering of the OMT-medication during pregnancy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|